These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 18178090)

  • 21. Studies towards the identification of a new generation of atypical antipsychotic agents.
    Garzya V; Forbes IT; Gribble AD; Hadley MS; Lightfoot AP; Payne AH; Smith AB; Douglas SE; Cooper DG; Stansfield IG; Meeson M; Dodds EE; Jones DN; Wood M; Reavill C; Scorer CA; Worby A; Riley G; Eddershaw P; Ioannou C; Donati D; Hagan JJ; Ratti EA
    Bioorg Med Chem Lett; 2007 Jan; 17(2):400-5. PubMed ID: 17084080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopamine D3 receptor antagonists as therapeutic agents.
    Joyce JN; Millan MJ
    Drug Discov Today; 2005 Jul; 10(13):917-25. PubMed ID: 15993811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and evaluation of indolebutylamines as a novel class of selective dopamine D3 receptor ligands.
    Du P; Xu L; Huang J; Yu K; Zhao R; Gao B; Jiang H; Zhao W; Zhen X; Fu W
    Chem Biol Drug Des; 2013 Sep; 82(3):326-35. PubMed ID: 23663349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists.
    Shimada I; Maeno K; Kondoh Y; Kaku H; Sugasawa K; Kimura Y; Hatanaka K; Naitou Y; Wanibuchi F; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2008 Mar; 16(6):3309-20. PubMed ID: 18083579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine D(3) receptor antagonists: The quest for a potentially selective PET ligand. Part two: Lead optimization.
    Micheli F; Holmes I; Arista L; Bonanomi G; Braggio S; Cardullo F; Di Fabio R; Donati D; Gentile G; Hamprecht D; Terreni S; Heidbreder C; Savoia C; Griffante C; Worby A
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4011-3. PubMed ID: 19553113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The structural evolution of dopamine D3 receptor ligands: structure-activity relationships and selected neuropharmacological aspects.
    Boeckler F; Gmeiner P
    Pharmacol Ther; 2006 Oct; 112(1):281-333. PubMed ID: 16905195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Orally active CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological activities of 1-benzazepine derivatives containing a sulfoxide moiety.
    Seto M; Miyamoto N; Aikawa K; Aramaki Y; Kanzaki N; Iizawa Y; Baba M; Shiraishi M
    Bioorg Med Chem; 2005 Jan; 13(2):363-86. PubMed ID: 15598559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modification of the clozapine structure by parallel synthesis.
    Su J; Tang H; McKittrick BA; Burnett DA; Zhang H; Smith-Torhan A; Fawzi A; Lachowicz J
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4548-53. PubMed ID: 16806922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hybrid approach for the design of highly affine and selective dopamine D(3) receptor ligands using privileged scaffolds of biogenic amine GPCR ligands.
    Sasse BC; Mach UR; Leppaenen J; Calmels T; Stark H
    Bioorg Med Chem; 2007 Dec; 15(23):7258-73. PubMed ID: 17826096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor.
    Shimada Y; Taniguchi N; Matsuhisa A; Akane H; Kawano N; Suzuki T; Tobe T; Kakefuda A; Yatsu T; Tahara A; Tomura Y; Kusayama T; Wada K; Tsukada J; Orita M; Tsunoda T; Tanaka A
    Bioorg Med Chem; 2006 Mar; 14(6):1827-37. PubMed ID: 16290163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Studies of new fused benzazepine as selective dopamine D3 receptor antagonists using 3D-QSAR, molecular docking and molecular dynamics.
    Liu J; Li Y; Zhang S; Xiao Z; Ai C
    Int J Mol Sci; 2011 Feb; 12(2):1196-221. PubMed ID: 21541053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design of novel hexahydropyrazinoquinolines as potent and selective dopamine D3 receptor ligands with improved solubility.
    Chen J; Ding K; Levant B; Wang S
    Bioorg Med Chem Lett; 2006 Jan; 16(2):443-6. PubMed ID: 16290142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists.
    Loiseau F; Millan MJ
    Eur Neuropsychopharmacol; 2009 Jan; 19(1):23-33. PubMed ID: 18793829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CoMFA and CoMSIA investigations of dopamine D3 receptor ligands leading to the prediction, synthesis, and evaluation of rigidized FAUC 365 analogues.
    Salama I; Schlotter K; Utz W; Hübner H; Gmeiner P; Boeckler F
    Bioorg Med Chem; 2006 Sep; 14(17):5898-912. PubMed ID: 16750374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The selection of a commercial route for the D1 antagonist Sch-39166.
    Hou D; Schumacher D
    Curr Opin Drug Discov Devel; 2001 Nov; 4(6):792-9. PubMed ID: 11899619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 'Click' D(1) receptor agonists with a 5-HT(1A) receptor pharmacophore producing D(2) receptor activity.
    Zhang J; Zhang H; Cai W; Yu L; Zhen X; Zhang A
    Bioorg Med Chem; 2009 Jul; 17(14):4873-80. PubMed ID: 19559623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and preliminary bioactivity evaluation of bitopic benzopyranomorpholine analogues as selective dopamine D3 receptor ligands as anti-drug addiction therapeutic agents.
    Cai J; Huang M; Wang Y; Chen X; Ji M
    Bioorg Med Chem Lett; 2021 Sep; 48():128269. PubMed ID: 34284107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 1,2,4-triazol-3-yl-thiopropyl-tetrahydrobenzazepines: a series of potent and selective dopamine D(3) receptor antagonists.
    Micheli F; Bonanomi G; Blaney FE; Braggio S; Capelli AM; Checchia A; Curcuruto O; Damiani F; Fabio RD; Donati D; Gentile G; Gribble A; Hamprecht D; Tedesco G; Terreni S; Tarsi L; Lightfoot A; Stemp G; Macdonald G; Smith A; Pecoraro M; Petrone M; Perini O; Piner J; Rossi T; Worby A; Pilla M; Valerio E; Griffante C; Mugnaini M; Wood M; Scott C; Andreoli M; Lacroix L; Schwarz A; Gozzi A; Bifone A; Ashby CR; Hagan JJ; Heidbreder C
    J Med Chem; 2007 Oct; 50(21):5076-89. PubMed ID: 17867665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exploration of the amine terminus in a novel series of 1,2,4-triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists.
    Micheli F; Arista L; Bertani B; Braggio S; Capelli AM; Cremonesi S; Di-Fabio R; Gelardi G; Gentile G; Marchioro C; Pasquarello A; Provera S; Tedesco G; Tarsi L; Terreni S; Worby A; Heidbreder C
    J Med Chem; 2010 Oct; 53(19):7129-39. PubMed ID: 20839775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route.
    Blagg J; Allerton CM; Batchelor DV; Baxter AD; Burring DJ; Carr CL; Cook AS; Nichols CL; Phipps J; Sanderson VG; Verrier H; Wong S
    Bioorg Med Chem Lett; 2007 Dec; 17(24):6691-6. PubMed ID: 17976986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.